Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P23276

UPID:
KELL_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P23276; B2RBV4; Q96RS8; Q99885

BACKGROUND:
Kell blood group glycoprotein, with UPACC code P23276, functions as a zinc endopeptidase, exhibiting a strong preference for endothelin-3 (EDN3) among the endothelins it can process. This specificity underlines its significant role in the modulation of endothelin-mediated signaling pathways, which are crucial for maintaining vascular tone and function.

THERAPEUTIC SIGNIFICANCE:
Exploring the enzymatic function of Kell blood group glycoprotein in endothelin processing reveals its potential as a therapeutic target. Given its preference for EDN3, strategies aimed at modulating its activity could lead to novel treatments for diseases associated with endothelin dysregulation, highlighting the therapeutic promise of this protein.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.